1、 Like many big pharmas facing a generics threat, Pfizer is slimming down and restructuring.
辉瑞和其它大制药公司一样都面临着非专利药的威胁，辉瑞公司正进行战略性收缩和重塑。
来源:
2、 For pharmas, personalized medicine could bring big profits. But for the broader public, the stakes are much higher.
对于药厂来说，个性化药物可以带来巨大的利润，但对公众来说，这是更是一个关键的赌注。
来源:
中